Senzime AB
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Senzime AB (publ) is a medical technology company specializing in developing and commercializing advanced monitoring solutions for patient safety in perioperative care and critical care environments. The company's core products include the Root® monitoring platform and associated disposable sensors, designed to facilitate real-time monitoring of vital signs, oxygen levels, and neuromuscular function; these products support anesthesiologists and critical care providers in managing patient care more effectively. Senzime offers a range of proprietary disposable sensors and software solutions that integrate with the Root® system, enhancing clinical decision-making through data-driven insights. The company operates primarily in the European market but is expanding globally through strategic partnerships and distribution agreements. Founded in 2009 and headquartered in Lund, Sweden, Senzime focuses on innovative healthcare solutions that improve patient outcomes and safety. Recent company developments include strategic collaborations with healthcare providers and distributors to expand its market reach, alongside ongoing efforts to launch new disposable sensor variants and software updates that enhance the Root® platform's functionality. These initiatives align with Senzime's strategic ambition to broaden its footprint in critical care and perioperative monitoring segments. The company's business segments encompass medical devices for monitoring, services related to training and support, and ongoing R&D activities to introduce next-generation monitoring technologies. Senzime continually strengthens its presence through targeted acquisitions, funding rounds, and technological enhancements to maintain a competitive edge in the medical technology industry.
Company News
New Scientific Evidence Presented at ANESTHESIOLOGY 2026 Strengthens the Case for Senzime's TetraGraph and Quantitative Neuromuscular Monitoring
Senzime Launches Industry-First Predictive Neuromuscular Monitoring Technology
Senzime Reaffirms Its Target of Reaching Positive Cash Flow Within Q4 2026
Senzime AB (publ) (SNZZF) Discusses Market Update, Philips Partnership, OEM Business Insights and Financing Package Transcript
Senzime Strengthens Financing to Support Strategic OEM Expansion and Path to Profitability
Senzime Secures Additional Major US Hospital Network Contract, Expanding Adoption of its Next-generation Neuromuscular Monitoring Technology
Senzime Awarded Exclusive 5-Year National Supply Contract with U.S. Veterans Affairs Through Its Partner TrillaMed
Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Transcript
Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Prepared Remarks Transcript
Interim Report Q2 2026: Strong Sensor Sales and Improved Margins, Despite Continued U.S. Monitor Market Headwinds
Senzime and Philips Medical Systems Enter Development and Commercialization Partnership
Invitation to Presentations of Senzime's Second Quarter 2026 Report
Senzime's TetraGraph System Receives ANVISA Regulatory Approval in Brazil
Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026
Senzime Strengthens Position in Pediatric Anesthesia by Securing Another Hospital Contract and Highlighting Positive Outcome Data
Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor
From Science to Practice: Senzime Obtains FDA 510(k) Clearance for Enhanced TetraGraph System
Bulletin From Annual General Meeting in Senzime AB (publ)
Senzime Strengthens U.S. Operations with New Leadership Appointments
Senzime AB (publ) (SNZZF) Q1 2026 Earnings Call Transcript